 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Ceralasertib (AZD6738) combined with paclitaxel may be effective in treating PD1/L1 drug-resistant melanoma

Clin Cancer Res: Ceralasertib (AZD6738) combined with paclitaxel may be effective in treating PD1/L1 drug-resistant melanoma

 Last Update: 2021-09-11
 Source: Internet
 Author: User

Tags

paroxetine 10 mg

opsumit 10 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Ceralasertib (AZD6378) is a new selective orally active serine/threonine protein (ATP) kinase inhibitor under AstraZeneca.

Recently, the international journal " Clin Cancer Res " published a new phase 1 clinical trial result of Ceralasertib combined with paclitaxel for refractory cancer: Ceralasertib's recommended phase 2 dose (RP2D) and preliminary anti-tumor activity and safety

Clin Cancer Res Clin Cancer Res Ceralasertib's recommended phase 2 dose (RP2D) and preliminary anti-tumor activity and safety Ceralasertib's recommended phase 2 dose (RP2D) and preliminary anti-tumor activity and safety

In this trial, patients with solid tumors (mostly melanoma) received Ceralasertib combined with fixed-dose paclitaxel (80 mg/m2, 1/8/15 days) treatment, 28 days as a course of treatment

Adverse reactions with incidence> 10%

Ceralasertib's RP2D is determined to be 240 mg BD, continuous medication on days 1-14, combined with paclitaxel 80 mg/m2 (day 1/8/15), 28 days as a course of treatment

Progression-free survival of 33 melanoma patients

In the overall analysis of 57 patients, the objective response rate (ORR) was 22.

Ceralasertib combined with paclitaxel is well tolerated and exhibited anti-tumor activity for advanced malignant tumors.

Original source:

Seung Tae Kim, et al.

Phase I Study of Ceralasertib (AZD6738) , a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

N-Desmethyl Imatinib 99%

CAS No.: 404844-02-6

Pharma Grade

$1/MT FOB

Topotecan HCl CAS 119413-54-6 for Scientific Research Chemical Reagents Use only topetecan hydrochloride

CAS No.: 119413-54-6

Pharmacy Grade

$4-5/G FOB

Regorafenib 98% white powder 755037-03-7 Regorafenib (BAY 73-4506)

CAS No.: 755037-03-7

Pharmacy Grade

$4-5/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.